FDA critic calls for independent post-market device, drug oversight

03/11/2013 | MassDevice.com (Boston)

The responsibility of overseeing market-available drugs and devices should be transferred from the FDA to an independent bureau similar to the National Transportation Safety Board, Dr. Robert Hauser argued at the American College of Cardiology conference. "The FDA is being asked to approve devices and then to be responsible for monitoring performance for devices and drugs," Hauser said. "Right away, you have a conflict because the group that approved the drug is going to question the group that is now criticizing the drug.

View Full Article in:

MassDevice.com (Boston)